Insurance Dispute Followed Rare Tumor Diagnosis
A Texas family faced coverage barriers after a doctor prescribed an off-label cancer medication.
Updated on Sept. 21, 2026 in Cancer
Mason Henderson, who was diagnosed with diffuse hemispheric glioma, died on May 4, 2026, following a prolonged struggle to secure access to a treatment. The case highlights the complexities patients face when insurance providers deny coverage for medications that lack a specific FDA-approved label for their rare condition.
Why it matters
Insurers frequently deny coverage for treatments when clinical evidence does not align with specific FDA labeling requirements. For patients in Houston and beyond, this barrier necessitates complex appeal processes or seeking compassionate-use donations when standard pathways are closed.
Doctors prescribed Lynparza based on the tumor's genetic language, though it lacks an FDA-approved label for diffuse hemispheric glioma. The patient received the medication for nearly two months after an appeal resulted in a donated supply.
The players
AstraZeneca
A pharmaceutical company that develops treatments for oncology, including PARP inhibitors like Lynparza.
Liviniti
A pharmacy benefit manager that handles coverage determinations and drug access for health plans.
Mason Henderson
A patient diagnosed with diffuse hemispheric glioma who sought treatment access.
The details
Lynparza is a PARP inhibitor that functions by targeting DNA damage response pathways in cancer cells, theoretically preventing them from repairing themselves. Because the medication was not explicitly approved for this rare brain tumor, local and institutional insurers denied reimbursement. The patient's family ultimately secured the medication through an appeal to the manufacturer, AstraZeneca, after initially being denied.
Timeline
Jan 16, 2026: Physician prescribes Lynparza to the patient.
Jan 30, 2026: Liviniti pharmacy benefit manager denies coverage for the drug.
March 2026: AstraZeneca initially denies the request for a medication donation.
March 9, 2026: AstraZeneca approves the donation of 60 pills.
May 4, 2026: Mason Henderson dies of the brain tumor.
Health Landscape
The clinical standard for oncology often relies on the FDA’s drug approval labeling system to guide insurance coverage and reimbursement. This case underscores the ongoing gap between precision medicine, which uses genetic tumor profiling, and the administrative policies that restrict drug access.
Patients with rare diagnoses should discuss the process for requesting off-label coverage with their medical team early in the treatment planning phase. It is also worth asking your provider if there are established patient assistance programs available through manufacturers for expensive, non-covered medications.
The takeaway
Insurance coverage for off-label use is often constrained by strict FDA labeling, creating significant hurdles for patients with rare, genetically profiled tumors. Patients should clarify the status of insurance approvals for specialized treatments and explore manufacturer compassionate-use programs with their care team.
Further reading
For more on navigating care and treatment pathways, see our resources on Cancer.
